Oct 14, 2020
CEO of MediSieve Gives an Interview to ADLIB Recruitment
Product | People | Potential article series of ADLIB released an interview with MediSieve's CEO George Frodsham
The purpose of the series is to showcase UK's best start-ups with the most potential, to share insider stories and to get a glimpse into future developments.
ADLIB Recruitment is an employee-owned Recruitment Agency operating within the Technology, Data, Engineering, Science, Sustainability, eCommerce, Marketing and Design sectors. However, their mission and impact go far beyond recruitment. ADLIB aims to connect ambitious organisations with equally ambitious talent, by immersing themselves in the worlds they operate in. ADLIB has analysed and identified specific Sustainable Development Goals and is committed to creating a working environment that is inclusive, empowering and respectful. Recently the company has pledged to support the Sustainable Development Goals raised by WHO as well as taken part in the Our Forest of Avon Trust Pledge.
In ADLIB's Product | People | Potential article series George talked about the origins and inspiration of MediSieve, as well as the difficulties of finding the right team members. When asked about the challenges in getting investors interested George stated:
"You have got to sell the vision and the dream and make investors believe in the change that you are trying to implement in the world and then show them it can be real."
That is exactly the spirit and goal of MediSieve: to provide doctors with a tool that removes harmful blood components of bloodborne diseases and to provide patients with treatment with the least side effects possible.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: